Success Metrics

Clinical Success Rate
80.0%

Based on 4 completed trials

Completion Rate
80%(4/5)
Active Trials
1(14%)
Results Posted
75%(3 trials)
Terminated
1(14%)

Phase Distribution

Ph phase_2
2
29%
Ph phase_3
1
14%
Ph phase_4
1
14%
Ph phase_1
1
14%

Phase Distribution

1

Early Stage

2

Mid Stage

2

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
1(20.0%)
Phase 2Efficacy & side effects
2(40.0%)
Phase 3Large-scale testing
1(20.0%)
Phase 4Post-market surveillance
1(20.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

66.7%

4 of 6 finished

Non-Completion Rate

33.3%

2 ended early

Currently Active

1

trials recruiting

Total Trials

7

all time

Status Distribution
Active(1)
Completed(4)
Terminated(2)

Detailed Status

Completed4
Recruiting1
Withdrawn1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
1
Success Rate
80.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (20.0%)
Phase 22 (40.0%)
Phase 31 (20.0%)
Phase 41 (20.0%)

Trials by Status

recruiting114%
completed457%
withdrawn114%
terminated114%

Recent Activity

1 active trials
Showing 5 of 7
recruitingphase_1

A Study to Investigate Andexanet Dosing and the Interaction Between Andexanet and Subsequent Enoxaparin in Healthy Participants

NCT07312851
completed

Retrospective Study on Characteristics and Outcomes in Hospitalised Patients Treated With Ondexxya

NCT05898412
withdrawnphase_3

A Study of Andexanet Alfa in Patients Requiring Urgent Surgery or Procedure

NCT05926349
completedphase_4

Trial of Andexanet Alfa in ICrH Patients Receiving an Oral FXa Inhibitor

NCT03661528
completed

Andexanet Alfa and 4F-PCC Use in Patients Hospitalised With an Anticoagulant-related Major Bleed

NCT05548777
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT07312851Phase 1

A Study to Investigate Andexanet Dosing and the Interaction Between Andexanet and Subsequent Enoxaparin in Healthy Participants

Recruiting
NCT05898412

Retrospective Study on Characteristics and Outcomes in Hospitalised Patients Treated With Ondexxya

Completed
NCT05926349Phase 3

A Study of Andexanet Alfa in Patients Requiring Urgent Surgery or Procedure

Withdrawn
NCT03661528Phase 4

Trial of Andexanet Alfa in ICrH Patients Receiving an Oral FXa Inhibitor

Completed
NCT05548777

Andexanet Alfa and 4F-PCC Use in Patients Hospitalised With an Anticoagulant-related Major Bleed

Completed
NCT04233073Phase 2

Trial of Andexanet in Patients Receiving an Oral FXa Inhibitor Who Require Urgent Surgery

Terminated
NCT03310021Phase 2

A Healthy Volunteer Pharmacokinetics (PK)/Pharmacodynamics (PD), Safety and Tolerability Study of Andexanet in Healthy Japanese and Caucasian Subjects

Completed

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7